tirzepatide jonesboro ar Raleigh, N.C Jonesboro, AR

Tirzepatide Side Effects# Well-characterized from Phase 3 (SURPASS, SURMOUNT) trials and post-market surveillance: Gastrointestinal : Nausea (12-33%), diarrhea (12-21%), vomiting (5-12%), constipation (6-11%) Decreased appetite : Common and expected pharmacological effect Injection site reactions : Mild, occurring in 2-5% of patients Pancreatitis : Rare

There was no difference between arms in weight at 6 months (BW:2.0 kg, 4.2, 8.1, p = 0.50), however, at 12 months weight was significantly higher in the liraglutide arm (BW:8.2 kg, 1.6, 14.9, p = 0.02)

Patients change doses, switch insurance, and prescriptions expire

To confirm that the effects on DA Gsta4 OPC differentiation upon extended in vitro expansion were dependent on Gsta4 we performed knock-down of Gsta4 using siRNAs